{"id":"W3009751715","doi":"10.1038/s41375-020-0776-2","title":"European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia","year":2020,"lang":"en","type":"review","venue":"Leukemia","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":1510,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Toronto","funders":"Daiichi Sankyo Europe; Scheme for Promotion of Academic and Research Collaboration; Sun Pharma; Servier; Astellas Pharma; Incyte; Italfarmaco; Seagen; Agios Pharmaceuticals; Astex Pharmaceuticals; Celgene; Daiichi-Sankyo; National Institute for Health and Care Research; Teva Pharmaceutical Industries; Gilead Sciences; Ariad Pharmaceuticals; Amgen; Pfizer; Ascentage Pharma","keywords":"Medicine; Dasatinib; Nilotinib; Bosutinib; Discontinuation; Imatinib; Myeloid leukemia; Tyrosine-kinase inhibitor; Internal medicine; Oncology; Intensive care medicine","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.04811984751068918,"score_gpt":0.3335786658783663,"score_spread":0.2854588183676771,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}